Ipamorelin

Ipamorelin is a synthetic pentapeptide growth hormone secretagogue that selectively agonizes the ghrelin/GHSR receptor. It is distinguished in research by its high selectivity for GH release without significant effects on ACTH, cortisol, or prolactin levels in preclinical models.

Ipamorelin is a synthetic pentapeptide that selectively activates the ghrelin/GHSR receptor to stimulate growth hormone release. It is valued in research for its high selectivity and minimal off-target neuroendocrine effects. Supplied as a lyophilized research peptide.

Ipamorelin was first described by Raun et al. in 1998 following systematic screening of peptide libraries for growth hormone secretagogue activity. It was identified as one of the most selective GHSR agonists, with minimal activity at other neuroendocrine targets — a characteristic that has made it a valuable tool in GH axis research.

Preclinical studies have demonstrated that Ipamorelin stimulates GH release in a dose-dependent manner via the GHSR pathway, with minimal effects on ACTH, cortisol, prolactin, or aldosterone. Animal studies report clean GH secretion profiles with rapid onset. Research continues into its pulsatile GH release kinetics and applications in neuroendocrine signaling studies.